PMID- 15536606
OWN - NLM
STAT- MEDLINE
DCOM- 20041130
LR  - 20221207
IS  - 0026-0495 (Print)
IS  - 0026-0495 (Linking)
VI  - 53
IP  - 11
DP  - 2004 Nov
TI  - Interstitial glucose kinetics in subjects with type 1 diabetes under physiologic 
      conditions.
PG  - 1484-91
AB  - We investigated the dynamic relationship between interstitial glucose (IG) in the 
      subcutaneous adipose tissue and plasma glucose (PG) during physiologic conditions 
      in type 1 diabetes mellitus (T1DM). Nine subjects with T1DM (5/4 M/F; age, 33 +/- 
      13 years; body mass index, 26.6 +/- 4.3 kg/m(2); glycosylated hemoglobin 
      [HbA(1c)], 8.6% +/- 0.9%; mean +/- SD) treated by continuous subcutaneous insulin 
      infusion (CSII) with insulin lispro were studied over 12 hours after a standard 
      meal (40 g carbohydrate [CHO]) and prandial insulin. IG was measured by open flow 
      microperfusion. Nine compartment models were postulated to account for temporal 
      variations in the IG/PG ratio. The models differed in the inclusion of 
      physiologically motivated alterations of pathways entering/leaving the IG 
      compartment in the adipose tissue. The best model included zero order (constant) 
      glucose disposal from the interstitial fluid (ISF) and insulin-stimulated glucose 
      transfer from plasma to the ISF. The former effect is expressed by a positive 
      association between the IG/PG ratio and PG, eg, a decrease in PG from 9 to 3.3 
      mmol/L lowers the IG/PG ratio by 0.1. The latter effect results in the IG/PG 
      ratio to be increased by 0.03 per 10 mU/L of plasma insulin. We were not able to 
      detect the stimulatory effect of insulin on glucose disappearance from the ISF. 
      In conclusion, we developed and quantified a model of IG kinetics in the adipose 
      tissue applicable to physiologic conditions in subjects with T1DM.
FAU - Wilinska, Malgorzata E
AU  - Wilinska ME
AD  - Department of Paediatrics, University of Cambridge, Addenbrooke's Hospital, 
      Cambridge CB2 2QQ, UK.
FAU - Bodenlenz, Manfred
AU  - Bodenlenz M
FAU - Chassin, Ludovic J
AU  - Chassin LJ
FAU - Schaller, Helga C
AU  - Schaller HC
FAU - Schaupp, Lukas A
AU  - Schaupp LA
FAU - Pieber, Thomas R
AU  - Pieber TR
FAU - Hovorka, Roman
AU  - Hovorka R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Insulin Lispro)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adipose Tissue/*metabolism
MH  - Adult
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 1/drug therapy/*metabolism
MH  - Drug Delivery Systems
MH  - Female
MH  - Glucose/*metabolism
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage
MH  - Injections, Subcutaneous
MH  - Insulin/administration & dosage/*analogs & derivatives
MH  - Insulin Lispro
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - Models, Theoretical
EDAT- 2004/11/13 09:00
MHDA- 2004/12/16 09:00
CRDT- 2004/11/13 09:00
PHST- 2004/11/13 09:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/11/13 09:00 [entrez]
AID - S0026049504002458 [pii]
AID - 10.1016/j.metabol.2004.05.014 [doi]
PST - ppublish
SO  - Metabolism. 2004 Nov;53(11):1484-91. doi: 10.1016/j.metabol.2004.05.014.